Board changes at Boehringer Ingelheim
pharmafile | May 22, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Boehringer, baiker
Boehringer’s Professor Wolfram Carius is stepping down from the Board to be replaced by Dr Wolfgang Baiker.
Carius who is a member of the Board of managing directors at the German firm has responsibility for biopharmaceuticals and production, and has decided to leave the corporation at the end of June.
Carius has been with Boehringer for over 26 years. Part of his time was spent in charge of the production site in Brazil, where he played a significant part in the building up and expansion of biopharmaceuticals. From 2005 to 2008, he was corporate division head, responsible for Boehringer Ingelheim’s worldwide pharma production network.
Boehringer has appointed in his place Dr Wolfgang Baiker (pictured) as a new member of the BMD. He will join the BMD in June, and from July will take over responsibility for biopharmaceuticals and production.
Baiker has been with the company since 1989 and has during this time held various functions in the Corporate Board Division Research, Development and Medicine in the US and at the German sites in Biberach and Ingelheim (at corporate headquarters).
Christian Boehringer, chairman of the shareholders’ committee and Professor Andreas Barner, chairman of the Board of managing directors at Boehringer stated: “We would like to thank Professor Carius for his thoroughly committed and very successful contribution to the company over many years. We are sad to see his departure and wish him all the best on his professional and personal way ahead.”
Related Content
Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3
Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 …
Boehringer withdraws its £700m investment in Hikma Pharmaceuticals
Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the …
Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype
The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment …
